NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score

INTRODUCTION: Currently in China, many immune checkpoint inhibitors (ICIs) have been approved for the treatment of non-small cell lung cancer (NSCLC). Some patients can not benefit from ICIs, and approximately 50% of patients have immunotherapy-related toxicity. Therefore, it is necessary to monitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Peng, Yang, Dongliang, Cui, Xiaoxia, Wang, Hanping, Si, Xiaoyan, Zhang, Xiaotong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381788/
https://www.ncbi.nlm.nih.gov/pubmed/32765097
http://dx.doi.org/10.2147/CMAR.S257967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381788/
https://www.ncbi.nlm.nih.gov/pubmed/32765097
http://dx.doi.org/10.2147/CMAR.S257967

Ejemplares similares